We are live on ! Find out more
AWGLSCP

ABG-WTT Global Life Science Capital Partners Portfolio holdings

AUM $12.3M
1-Year Est. Return 3.13%
This Fund
S&P 500
This Quarter Est. Return
+5.41%
1 Year Est. Return
-3.13%
3 Year Est. Return
+108.96%
5 Year Est. Return
-90.91%
10 Year Est. Return
–
AUM
$26.8M
AUM Growth
-$11.6M
Cap. Flow
-$12.5M
Cap. Flow %
-46.87%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
–
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$12.1M
2
LUNG icon
Pulmonx
LUNG
+$405K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBLL
1
CeriBell Inc
CBLL
$714M
$20.4M 76.17%
1,088,101
– –
RPID icon
2
Rapid Micro Biosystems
RPID
$86.2M
$6.38M 23.83%
1,848,296
– –
CGON icon
3
CG Oncology
CGON
$6.66B
– –
-495,526
Closed -$12.1M
LUNG icon
4
Pulmonx
LUNG
$87.6M
– –
-60,204
Closed -$405K

Similar funds

M
MetLife New York $12.3M AUM 29% 1-Year Est. Return
MAMNY
Marathon Asset Management (New York) New York $12M AUM 8.79% 1-Year Est. Return
IWM
Immaculate Wealth Management Mesa, Arizona $12.7M AUM
VH
Vitol Holding Rotterdam, Netherlands $11.9M AUM 27.28% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
CCM
Crabel Capital Management Los Angeles, California $10.8M AUM 3.34% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $10.8M AUM 61.97% 1-Year Est. Return

ABG-WTT Global Life Science Capital Partners's Q2 2025 Portfolio in Review

As of Q2 2025, ABG-WTT Global Life Science Capital Partners held 4 positions worth $26.8M, down 30% from $38.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ABG-WTT Global Life Science Capital Partners withdrew a net $12.5M in Q2 2025, closing 2 positions. Its most notable exit was CG Oncology, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ABG-WTT Global Life Science Capital Partners fully exited CG Oncology in Q2 2025, selling an estimated $12.1M.
  • ABG-WTT Global Life Science Capital Partners's ten largest holdings make up 100% of its $26.8M portfolio in Q2 2025.
  • ABG-WTT Global Life Science Capital Partners opened 0 new positions and closed 2 in Q2 2025.
  • ABG-WTT Global Life Science Capital Partners's portfolio value fell 30% quarter-over-quarter to $26.8M.

Based on ABG-WTT Global Life Science Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.